HepNet Logo (EUIPO, 09/14/2023)
EUIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The Union trademark HepNet was filed as Figurative mark on 09/14/2023 at the European Union Intellectual Property Office.
It was registered as a trademark on 01/24/2024.
The current status of the mark is "Trademark registered".
Logodesign (Wiener Klassifikation)
#One line or one band #Oblique lines or bands #Letters crossed or barred by letters, numerals or a figurative element
| Trademark form | Figurative mark |
| File reference | 018925556 |
| Application date | September 14, 2023 |
| Publication date | October 17, 2023 |
| Entry date | January 24, 2024 |
| Expiration date | September 14, 2033 |
Trademark owner
4 Kingdom Street
W2 6BD London
GB
W2 6BD London
GB
Trademark representatives
Varso Tower Chmielna 69
00-801 Warsaw
PL
goods and services
5
Pharmaceutical and medical preparations for use in targeting genes and silencing or inhibiting gene expression; drug delivery agents that facilitate the delivery of pharmaceutical preparations targeting genes and silencing or inhibiting gene expression; drug delivery agents that facilitate the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs); drug delivery agents that facilitate the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs), all for targeting genes and silencing or inhibiting gene expression; RNAi-based medicines and pharmaceuticals; short interfering RNA-based (siRNA) medicines and pharmaceuticals; nucleic acid-based drugs (NABDs); pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation
9
Computer software for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; artificial intelligence and machine learning software for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; electronic databases for use in the field of pharmaceuticals, medicines and drug discovery, namely, databases containing information relating to potential biological drug targets and gene-disease associations; computer platform software for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; computer software platforms for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; computer software enabling the searching and retrieval of data relating to pharmaceuticals, medicines and drug discovery; software for the analysis of data relating to pharmaceuticals, medicines and drug discovery; search engine software for use in the field of pharmaceuticals, medicines and drug discovery; search engine software for the searching, retrieval, indexing and analysis of data relating to pharmaceuticals, medicines and drug discovery
40
Custom manufacture of pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; custom manufacture of RNAi-based pharmaceuticals and medicines; custom manufacture of short interfering RNA (siRNA) medicines; custom manufacture of nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression; custom manufacture of pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid
42
Scientific research and development in the field of targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to RNAi-based pharmaceuticals and medicines; scientific, pharmaceutical and medical research and development services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking gene expression, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and, pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; drug discovery services relating to RNAi-based pharmaceuticals and medicines; drug discovery services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; drug discovery services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; scientific and technical testing and data analysis in relation to pharmaceuticals and medicines; scientific and technical testing and data analysis in relation to RNAi-based medicines; scientific and technical testing and data analysis in relation to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific and technical testing and data analysis in relation to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; design, development, creation and maintenance of computer platforms and computer software for use in the field of pharmaceuticals, medicines and drug discovery; design, development, creation and maintenance of computer platforms and computer software enabling the searching and retrieval of data relating to pharmaceuticals, medicines and drug discovery; design, development, creation and maintenance of computer platforms and computer software for the analysis of data relating to pharmaceuticals, medicines and drug discovery; design, provision and operation of search engine software for use in the field of pharmaceuticals, medicines and drug discovery; design, provision and operation of search engine software for the searching, retrieval, indexing and analysis of data relating to pharmaceuticals, medicines and drug discovery; Platform as a Service (PaaS) services relating to the use of artificial intelligence and machine learning software and databases in the field of pharmaceuticals, medicines and drug discovery; Platform as a Service (PaaS) services relating to the use of artificial intelligence and machine learning software and databases in relation to RNAi-based medicines and pharmaceuticals, short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; design and development of computer-simulated models for use in the field of pharmaceuticals, medicines and drug discovery; providing non-downloadable computer software for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; Software as a Service (SaaS) services relating to the use of artificial intelligence and machine learning software and databases in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; Software as a Service (SaaS) services relating to the use of artificial intelligence and machine learning in relation to RNAi-based medicines and pharmaceuticals, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid
Trademark history
| Date | Document number | Area | Entry |
|---|---|---|---|
| October 30, 2024 | Change Representative, Published |
ID: 11018925556